Myovant Sciences Ltd. named Kim Sablich chief commercial officer.
Sablich was GlaxoSmithKline PLC's vice president of primary care marketing in the U.S.
Myovant also added Myrtle Potter, Mark Guinan and Frank Torti to its board of directors.
Potter, who is the operating chair at Roivant Sciences Ltd.'s Roivant Pharma division, was also named chairman of the Myovant board.
Guinan is CFO and executive vice president at Quest Diagnostics Inc.
Torti is vant investment chair at Roivant Pharma.
London-based Myovant develops therapies for women's health and endocrine diseases.
